Maze Therapeutics (NASDAQ: MAZE), a clinical-stage biopharmaceutical company based in South San Francisco focused on kidney and metabolic diseases, has priced a USD 150 million underwritten registered public offering of common stock and pre-funded warrants.
The offering, sole-underwritten by Leerink Partners, comprises 5,540,000 shares of common stock at USD 23.50 per share, alongside pre-funded warrants covering up to 850,000 additional shares priced at USD 23.499 each. Participating investors include Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management, along with several unnamed healthcare-focused funds. Maze said it intends to apply net proceeds toward advancing its lead pipeline candidates and general corporate purposes, with the capital expected to fund operations into 2029.
The company's pipeline centers on two small molecule programs. MZE829 is a dual-mechanism APOL1 inhibitor currently in Phase II development for APOL1-mediated kidney disease, a genetically defined condition affecting a subset of patients with chronic kidney disease. MZE782, a SLC6A19 inhibitor, is advancing toward Phase II with potential applications in both phenylketonuria and chronic kidney disease. The dual-indication rationale for MZE782 reflects the biological overlap between amino acid transport dysfunction in PKU and renal tubular handling of solutes in CKD.
Both programs are guided by Maze's proprietary Compass platform, which integrates human genetic variant discovery and functional characterization to identify and validate small molecule targets. The approach prioritizes genetically supported mechanisms, using population-scale genomic data to identify variants associated with disease protection or susceptibility, then functionalizing those variants to inform drug design. The platform is positioned within a broader industry trend toward genetics-first drug discovery, where target selection is anchored in human genetic evidence rather than preclinical models alone.
Spot something wrong? Report an issue with this article